Related Experiment Video

Updated: Mar 31, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

2.4K

PARP inhibition: A promising therapeutic target in ovarian cancer

A Musella1, C Marchetti1, M L Gasparri2

  • 1University Sapienza of Rome Department of Gynecology, Obstetrics and Urological Sciences Rome Italy.

Cellular and Molecular Biology (Noisy-Le-Grand, France)
|November 1, 2015
PubMed

Insights

Poly (ADP-ribose) polymerase (PARP) inhibitors show promise for treating ovarian cancer, offering a new approach beyond traditional chemotherapy. Research is ongoing to determine their full impact on patient survival and drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian cancer has the highest mortality rate among gynecological cancers.
  • Current treatments like platinum-taxane chemotherapy and surgery have limited impact on overall survival due to drug resistance and recurrence.
  • Novel therapeutic targets are needed to improve outcomes for ovarian cancer patients.

Purpose of the Study:

  • To review recent research and clinical progress on poly (ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer treatment.
  • To explore PARP inhibitors as novel targeted agents for ovarian cancer therapy.

Main Methods:

  • Literature review of recent studies on PARP inhibitors in ovarian cancer.
  • Analysis of clinical trial data and research on drug resistance mechanisms.
  • Examination of the role of PARP in DNA repair pathways and its inhibition.

Main Results:

  • PARP inhibitors target specific pathways involved in tumor growth, particularly DNA repair.
  • These inhibitors have shown activity in cancers with specific genetic mutations (e.g., BRCA) or DNA repair deficiencies.
  • PARP inhibitors are being investigated in clinical trials for their efficacy in ovarian cancer.

Conclusions:

  • PARP inhibitors represent a promising novel therapeutic strategy for ovarian cancer.
  • Further clinical investigation is crucial to establish the role and impact of PARP inhibitors in improving patient survival and overcoming drug resistance.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K